Evidence map›Paper›PMID 38051321›Full record

ArticleCalcified tissue international2024

An Additional Lrp4 High Bone Mass Mutation Mitigates the Sost-Knockout Phenotype in Mice by Increasing Bone Remodeling.

Gretl Hendrickx, Eveline Boudin, Ligia Mateiu, Timur A Yorgan, Ellen Steenackers, Michaela Kneissel, Ina Kramer, Geert Mortier, Thorsten Schinke, Wim Van Hul

Abstract read
PubMed Publisher
In one paragraph

Article in Calcified tissue international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Identifying rare variants in genes related to bone phenotypes in a cohort of postmenopausal women.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2025
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Gretl HendrickxCentre for Medical Genetics, University and University Hospital of Antwerp, Antwerp, Belgium.ORCID 0000-0001-6715-9241
Eveline BoudinCentre for Medical Genetics, University and University Hospital of Antwerp, Antwerp, Belgium.ORCID 0000-0003-4818-6804
Ligia MateiuCentre for Medical Genetics, University and University Hospital of Antwerp, Antwerp, Belgium.ORCID 0000-0002-2655-3581
Timur A YorganDepartment of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0002-0712-0983
Ellen SteenackersCentre for Medical Genetics, University and University Hospital of Antwerp, Antwerp, Belgium.
Michaela KneisselDiseases of Aging and Regenerative Medicine, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Ina KramerDiseases of Aging and Regenerative Medicine, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Geert MortierCentre for Medical Genetics, University and University Hospital of Antwerp, Antwerp, Belgium.ORCID 0000-0001-9871-4578
Thorsten SchinkeDepartment of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0002-8576-0177
Wim Van HulCentre for Medical Genetics, University and University Hospital of Antwerp, Antwerp, Belgium. wim.vanhul@uantwerpen.be.ORCID 0000-0002-5065-7858
Antwerp University Hospital · BENovartis (Switzerland) · CHUniversität Hamburg · DEUniversity of Antwerp · BE

Funding

Fonds Wetenschappelijk Onderzoek 12A3814NFonds Wetenschappelijk Onderzoek G031915NSeventh Framework Programme 602300Seventh Framework Programme SYBILUniversiteit Antwerpen FFB190208Universiteit Antwerpen GENOMED
6 · The paper itself

Abstract

Pathogenic variants disrupting the binding between sclerostin (encoded by SOST) and its receptor LRP4 have previously been described to cause sclerosteosis, a rare high bone mass disorder. The sclerostin-LRP4 complex inhibits canonical WNT signaling, a key pathway regulating osteoblastic bone formation and a promising therapeutic target for common bone disorders, such as osteoporosis. In the current study, we crossed mice deficient for Sost (Sost

Indexed as

Adaptor Proteins, Signal TransducingBone RemodelingHyperostosisSyndactylyAnimalsFemaleLDL-Receptor Related ProteinsMaleMiceMice, KnockoutMutationPhenotypeAdaptor Proteins, Signal TransducingLDL-Receptor Related ProteinsLrp4 protein, mouseSost protein, mouseHigh bone massLrp4RNA sequencingSclerosteosisSclerostinSost

Identifiers

PMID38051321
OpenAlexW4389334398

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.